ImmunoPrecise Antibodies Ltd.

(TSX-V:IPA.V) (OTCPK:IPATF)

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts

Exclusive Licensing Gives Biologics CROs Major Advantage

FN Media Group Presents Microsmallcap.com Market Commentary

 

New York, NY – April 26, 2019Biopharma companies rise and fall on the back of research and development. Success in the biopharma industry has always been about patents. The exclusive right to market life-saving treatments is how all the industry titans made their names. Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE) both amped up on R&D and the ensuing patents. As such, companies rise and fall on these developments, and can spend months, if not years, researching, developing, and testing a new compound. When they’re successful, these major breakthroughs can be worth billions in revenue for those who commercialize these drugs. Many biopharma companies, such as, AbbVie Inc. (NYSE:ABBV), Thermo Fisher Scientific Inc. (NYSE:TMO), and ImmunoPrecise Antibodies Ltd (OTCQB:IPATF) (TSX-V:IPA), are hitting home runs in the pharmaceutical discovery process, which lands them lucrative and exclusive contracts with big pharma.

 

As major firms continue to search for new potential proprietary breakthroughs, they have begun to recognize the value in outsourcing this process to smaller, more specialized companies. Often focused on highly niche areas, these small research firms have succeeded in securing exclusive agreements with major institutions simply because their expertise is so hard to come by. In turn, a large number of lucrative breakthroughs have come as a result of these partnerships, with many CROs poised to explode in value thanks to their success.

 

The Changing Nature of the Biopharma Discovery Process

 

Decades ago, drug makers did their own discovery work almost entirely in house. In the past few years, however, outsourcing this process has become increasingly common. The rapid growth of various Contract Research Organizations (CROs) in the niche biopharma world has attracted most of the experts in these specialized areas. This means that major companies looking to jump into areas such as gene therapy, biologics, and other niche sectors are better off working with these firms rather than competing with them. Some CROs, such as ImmunoPrecise Antibodies Ltd (OTCQB:IPATF) (TSX-V:IPA), bring decades worth of specialized expertise that is almost impossible to compete with.

 

Multi-billion-dollar pharmaceutical corporations such as Johnson & Johnson (NYSE:JNJ) have already begun incorporating various CROs into their research and development projects. According to one report[1], the global CRO market was valued at around $36 billion in 2017 and is expected to grow to $56 billion by 2023 as the demand for outsourcing testing and specialized expertise continues to grow.

 

This isn’t surprising, as it’s easier for large companies to outsource these programs –  that aren’t a core focus – to a more specialized company with expertise in that area. According to statistics released by global consulting firm Charles River Associates, around 75 percent[2] of new developments in niche biotech areas came from companies that aren’t commercializing the product. Even outside these specialized areas, CROs are expected to make over one-third[3] of all global drug-discoveries by 2021. This means most major discoveries aren’t coming from major companies such as Thermo Fisher Scientific Inc. (NYSE:TMO), but rather originate from highly experienced CROs.

 

Even industry leader Pfizer Inc. (NYSE:PFE) has already partnered with these types of companies. Signing an agreement with Pharmaceutical Product Development, this marks the third strategic CRO partner the company announced. At the time, Pfizer Inc. went on to say[4] that these partnerships are what will “provides us with additional flexibility” and the “enhanced global reach” necessary to ensure their portfolio remains competitive.

 

Major Breakthroughs

 

Thanks to these agreements, there has been an explosion of breakthroughs in the biopharma industry. One company that has partnered with AbbVie Inc. (NYSE:ABBV), Voyager Therapeutics, has been making progress in a potential treatment for Parkinson’s disease. Using vectorized antibodies targeted at specific proteins, Voyager’s new technology could revolutionize how the disease is treated and give hope to millions of Parkinson’s patients. If successful, such a treatment could be worth billions in revenue.

 

Another highly lucrative breakthrough was spearheaded by ImmunoPrecise Antibodies Ltd (IPATF) (IPA). Known as an industry leading CRO in the cutting edge field of biologics, ImmunoPrecise Antibodies Ltd (IPATF) (IPA) secured an exclusive license with Stanford University recently. The arrangement would see ImmunoPrecise Antibodies’ Ltd (IPATF) (IPA) wholly owned subsidiary, U-Protein Express, act as the exclusive provider of a highly specialized protein, Wnt surrogate-Fc.

 

Wnt proteins are used in the body to signal cells to multiply and grow. Wnt surrogate, on the other hand, can be used as a growth factor in developing specific tissues and even cultivating organ parts. The license awarded from Stanford University would make ImmunoPrecise Antibodies Ltd (IPATF) (IPA) the only manufacturer and supplier of Wnt surrogate Fc in the entire world. Currently, there are hundreds of research groups focused on the organoid space, an area that’s poised to expand considerably over the upcoming years. Almost all of these companies will end up requiring growth factor proteins such as Wnt surrogate in the future for their experiments.

 

As the only provider of this critical, niche compound, ImmunoPrecise Antibodies Ltd (IPATF) (IPA) has quickly cemented itself as a world-respected CRO and a cutting edge leader in the biopharma space.

 

Further Biopharmaceutical Developments

 

Pfizer Inc. (PFE) announced recently that it had seen excellent results from a phase 3 study evaluating one of their compounds, Tanezumab. The study had looked at the effects of the drug on patients with osteoarthritis. At the moment, the compound is part of an investigational class of non-opioid chronic pain medications that could revolutionize the market.

 

Johnson & Johnson (JNJ) also had good news regarding its own compound, Invokana (canagliflozin), which was found in a phase 3 study to drastically reduce the risk of renal failure in patients.  People with type 2 diabetes and chronic kidney disease may see this drug used in the future as a treatment option.

 

The Federal Drug Administration (FDA) recently gave approval of an interleukin-23 inhibitor called Skyrizi. The producer of the drug, AbbVie Inc. (ABBV), already has an impressive immunology portfolio treating a variety of conditions. Skyrizi, in particular, would seek to treat patients with moderate to severe plaque psoriasis.

 

As biopharma investors wait in anticipation for the sectors’ quarterly financial earnings, Thermo Fisher Scientific Inc. (TMO) impressed analysts with strong Q1 revenue figures. The company went on to say that its revenue grew by five percent year over year. First quarter revenues were at $6.12 billion, compared to the $5.85 billion during the same period last year.

 

For a FREE research report on ImmunoPrecise Antibodies Ltd (TSX.V:IPA) (OTCQB:IPATF), visit www.microsmallcap.com

 

DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

 

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of ImmunoPrecise Antibodies Ltd.

 

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

 

 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

 

Media Contact:
FN Media Group, LLC
info@financialnews.com
+1(561)325-8757

 

Source: Microsmallcap.com

 

[1] Business Wire Press Release, Nov 6, 2018
https://www.businesswire.com/news/home/20181106005397/en/Global-Contract-Research-Organizations-CRO-Market-Valued

[2] BioSpace, Sept 13, 2018

https://www.biospace.com/article/am6a-report-sheds-light-on-importance-of-licensing-agreements-in-biopharma-industry/

[3] Nature International Journal of Science, April 11, 2018

https://www.nature.com/articles/d41586-018-04163-8

[4] Outsourcing Pharma, April 21, 2015

https://www.outsourcing-pharma.com/Article/2015/04/22/Pfizer-reveals-PPD-as-third-strategic-CRO-partner

Monoclonal Antibody Therapy Drug Market on Trajectory Towards $140 Billion

New York, NY – April 4, 2019 – Timelines on the next generation of antibody discovery may be getting shorter. Potentially incentivized by a new study on the monoclonal antibody therapy market, analysts recently projected a double-digit 10.5% CAGR by 2022, and revenues to touch $140 billion. Driving this surge is the development of new therapeutic drugs from Big Pharma giants such as AbbVie Inc. (NYSE:ABBV), Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and Thermo Fisher Scientific Inc. (NYSE: TMO), as well as from contract research organizations (CROs) such as ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTC:IPATF).

 

Working hand in hand, Big Pharma has been increasingly leaning on CROs to help take care of the drug development. Each step along the way to discovery could require a different CRO—unless it’s done by full-service therapeutic drug developers ImmunoPrecise Antibodies Ltd. (IPA) (IPATF) who uniquely cover each step of the process from start to finish.

 

Founded in Victoria, Canada, ImmunoPrecise Antibodies Ltd. (TSX.V:IPA) (OTC:IPATF) recently expanded its footprint into the highly active pharmaceutical center, Massachusetts. The company formally launched a newly formed wholly-owned, Cambridge Massachusetts-based subsidiary, called Talem Therapeutics.

 

The main mission of Talem is to focus on the discovery and development of next-generation, fully-human, monoclonal therapeutic antibodies targeting neurology, immuno-oncology, gastroenterology, inflammation, and rare/specialty diseases. Using proprietary antibody discovery platforms and innovative technologies, Talem will be producing a rich pipeline of high quality and distinct antibodies.

 

Research Leading to Discoveries

 

Domestically, the US drug industry spends approximately $45 billion annually on research and development (R&D). Majority of the research is going into biologics (vaccines, blood components, gene therapy, etc)—a sector that’s growing the entire global pharmaceuticals market at a CAGR of 5.8%, from US$934.8 billion in 2017, to a projected US$1.17 trillion by 2021.

 

Embedded within the entire market is a niche that is still possibly being underserved. While the antibody discovery CRO segment topped over US$100 billion in 2017, it’s projected to grow to US$125 billion by 2020.

 

For CROs, success comes from increased exposure, as each new contract with Big Pharma enhances valuable and lucrative relationships. The CRO business is good, as exemplified by ImmunoPrecise Antibodies Ltd. (IPA) (IPATF) who saw its revenue increase in 2018 by 106%. The momentum has continued, as the company recently reported record Q3 2019 results, with revenues up 228% for the first 9 months of fiscal 2019.

 

According to a research report from Cormark, the company is expected to reach projects an impressive estimated run-rate tracking of CAD$16.6 million in fiscal 2019—tripling its 2018 numbers. By 2020, gross revenue is expected to hit CAD$31.9 million.

 

With operations now spread across the USA, Canada, and the EU, the company has established an impressive international presence. The announcement of the launch of Talem Therapeutics formally put ImmunoPrecise Antibodies Ltd. (IPA) (IPATF) in the same area code as some of the majors they want to provide services for, such as Pfizer Inc. (NYSE:PFE) that has its 280,000 sq ft state-of-the-art R&D hub also located in Cambridge, Massachusetts.

 

The need for Talem was driven by demand for safe, therapeutic, monoclonal antibody (mAb) candidates with more complex target product profiles, all driving a need for more robust discoveries. Talem was founded to expedite the high-powered discovery and development of custom therapeutics produced as both internal assets for ImmunoPrecise Antibodies Ltd. (TSX.V:IPA) (OTC:IPATF) as well as in response to partnership requests of the company from Big Pharma.

 

Talem Therapeutics will develop on-demand and in-house antibodies through pre-clinical stage prior to licensing for clinical partners. Success for the new entity will likely be driven by the speed and adaptability of ImmunoPrecise’s platforms, which enable Talem to quickly respond to targets, built off years of experience and expertise in the antibody discovery sector. Along with the designated pre-clinical programs, Talem is already engaging in negotiations on joint research and development (R&D) programs with numerous pharmaceutical companies.

 

Under its umbrella, ImmunoPrecise Antibodies Ltd. (IPA) (IPATF) already has more than 200 clients, having also recently announced an agreement with an undisclosed top-15 global pharmaceutical company to discover novel antibodies using ImmunoPrecise’s proprietary hybridoma technology.

 

Further Monoclonal Antibody Therapy Developments

 

Developers of the psoriasis drug Skyrizi, AbbVie Inc. (NYSE:ABBV), are celebrating the drug’s recent approval in Japan. The potential blockbuster drug is being touted as important, especially due to sales of its Humira inflammatory disease mega-blockbuster having been affected by cheaper competitors outside of the US. AbbVie has also been linked to CRO Atomwise through a partnership announced by the CRO.

 

Pfizer Inc. (NYSE:PFE) recently stated it had acquired a 15% equity interest stake in privately-held gene therapy company Vivet, and secured an exclusive option to acquire all outstanding shares of the company. Pfizer openly said it will look to collaborate with Vivet on the development of VTX-801, which Is a proprietary treatment for the life-threatening liver disorder, Wilson disease.

 

Looking to secure its second multiple myeloma nod in newly diagnosed patients in the US, Johnson & Johnson (NYSE:JNJ) isn’t winning many friends with England’s cost watchdogs. The National Institute for Health and Care Excellence (NICE) agreed to back a multiple myeloma combo that includes J&J’s Darzalex, Takeda’s Velcade, and corticosteroid dexamethasone in patients who have received one previous treatment. However, the Cancer Drugs Fund (CDF) has only agreed to cover the first use and not routine use.

 

A top player in the Global Research Antibodies Market, Thermo Fisher Scientific Inc. (NYSE: TMO) is a world’s largest maker of scientific and laboratory equipment. In 2013 the company acquired biotechnology company Life Technologies for approximately US$13.6 billion. The acquisition catapulted  Thermo Fisher, to the forefront of the field of personalized medicine. In 2017 they acquired leading global manufacturer of drugs for clinical trials – Patheon N.V., for $5.2 billion. Patheon’s drug manufacturing capabilities under its arsenal of services enabled Thermo Fisher to grab a bigger slice of the contract development and manufacturing market.

 

For a FREE research report on ImmunoPrecise Antibodies Ltd. (TSX.V:IPA) (OTC:IPATF), visit www.microsmallcap.com.

 

 

DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

 

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of ImmunoPrecise Antibodies Ltd.

 

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

 

Media Contact:
FN Media Group, LLC
info@financialnews.com
+1(561)325-8757

Source: Microsmallcap.com

ImmunoPrecise Launches DeepDisplay(™) Antibody Discovery Platform

ImmunoPrecise Launches Large-Scale Discovery Program with US Pharma Company

 

Victoria, BC –  April 2, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the expansion of their service offerings in therapeutic antibody discovery to select rare, fully human antibodies using DeepDisplayTM, a combination of transgenic animal immunization and custom phage display antibody selections.

 

ImmunoPrecise has launched, in response to a large-scale discovery program with an unnamed, US-based Pharma company, a powerful and unique platform for therapeutic antibody discovery proven to be successful in delivering a sequence-diverse human antibody panel with broad species cross-reactivity (e.g. mouse, primate, human). The combination of a transgenic animal immunization with phage display antibody selection used in DeepDisplay™ delivers the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of success compared to conventional technologies.

 

“The ability to select needle-in-the-haystack antibodies using this powerful combination of OmniAb® rodent (mouse or rat) immunization and phage display antibody selections provide an entirely new avenue in therapeutic antibody discovery.” said Debby Kruijsen, Ph.D., General Manager of ModiQuest® Research.

 

Jennifer Bath, Ph.D., CEO of ImmunoPrecise added: “With over 15 years of experience in customized and precision-based phage display, IPA has coupled this powerful technology with Ligand’s OmniAb™ transgenic rodent platforms to enable the accelerated discovery of highly diverse, fully human antibodies with superior clinical safety and efficacy and the lowest immunogenicity.”

 

The data generated during the large pharma  and OmniAb collaboration will be publicly presented at conferences in Munich, Germany https://www.hub-xchange.com/europe-2019 and Boston, Massachusetts https://www.hub-xchange.com/us-east-coast-2018, in March and May, respectively, as well as via live webinar, details forthcoming.

 

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

 

ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

 

The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hybridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

 

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2018 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE ImmunoPrecise Antibodies Ltd.

About ImmunoPrecise Antibodies


 

Company Profile

ImmunoPrecise Antibodies Ltd. is a public company listed on the TSX Venture Exchange (TSXV: IPA) located in Victoria, British Columbia, Canada and preeminent supplier of custom antibodies to the global research industry and industrial community. Our dedication to advancing antibody development has resulted in cutting-edge immunological innovations. With over 25 years of experience in the custom antibody business, ImmunoPrecise provides high customer satisfaction through a customized professional approach.

 

ImmunoPrecise is comprised of experienced research and development scientists and encompasses a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. We pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving very thorough and professional service. We customize your project to generate antibodies that meet your specific needs. Our clients include: scientists in the biotech and pharmaceutical sector, academic researchers and those employed by government.

 

Company History

Since its inception in 1989, ImmunoPrecise has been serving clinical research and biological markets worldwide. With its beginnings in the Biochemistry/Microbiology department at the University of Victoria, ImmunoPrecise expanded and built a new Hybridoma Facility, at the Vancouver Island Technology Park (VITP) in 2005.

 

Robert Beecroft, Chief Technical Officer and Founder, has implemented 3 key methodologies that have allowed ImmunoPrecise to be set apart from other antibody companies: 1) the Rapid Prime immunization strategy in mice; 2) Single-Step cloning for HAT selection of hybridomas and 3) B-cell Selection-  recombinant monoclonal antibody technology for the generation of rabbit, rodent, and human monoclonal antibodies.

 

 

Technology

ImmunoPrecise uses proprietary and innovative inoculation and cloning technologies and established expertise to produce mAbs significantly faster than traditional methods of antibody production and has used these capacities to produce hundreds of mAbs, many of which are now being sold commercially through industry partners.

 

Operations

Our state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia house a Canadian Council for Animal Care (CCAC) animal care unit, tissue culture, and a B cell facility. ImmunoPrecise operates globally to offer antibody services from target analysis to pre-clinical lead generation, in collaboration with our subsidiary operations at U-Protein Express B.V., Utrecht, and ModiQuest Research B.V., Oss, both in the Netherlands.

 

 

PRODUCTS

 

Antibodies

ImmunoPrecise offers a selection of high quality antibody products to the research and industrial community. For further details, please view our complete list of antibodies.

 

Hybridoma Licensing

ImmunoPrecise is increasing its panel of antibodies specifically for out-licensing.

 

ImmunoPrecise’s proprietary technologies and products are positioned on the leading edge of antibody development, innovating our industry as a single source provider of the full compliment of antibody discovery platforms. As an investor in ImmunoPrecise Antibodies, you’re joining us at the forefront of new, exciting, and valuable advancements in next-generation antibody discovery.

 

Our Stock Quotes and Charts are available on our site. For more information, please review our Investor Presentation or visit our News & Releases page.

 

Financial Statements

 

Please find all of our financials at Sedar in English and Français

 

Investor Relations

 

For investor inquiries please contact:

Contact Financial,
Frédérick Chabot,
+1 (438) 863-7071,
frederick@contactfinancial.com

 

Source:  https://immunoprecise.com/

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated twenty five hundred dollars for ImmunoPrecise Antibodies Ltd. current news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF ImmunoPrecise Antibodies Ltd.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Sign Up & Get FREE News Alerts From FNM Today!